Stock Rating Upgrade
During the last several trading days the Value Trend Rating for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) improved from D to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock rose modestly by 0.5% on 1/17/25. The stock closed at $61.53. Moreover, trading volume in this advance was unusually high at 176% of normal. The stock has been weak relative to the market over the last nine months and has declined -10.0% during the last week.
Current PriceTarget Research Rating
Biomarin Pharmaceutical has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Biomarin Pharmaceutical has a neutral Appreciation Score of 59 and a slightly negative Power Rating of 33, resulting in the Low Neutral Value Trend Rating.
Be the first to comment